2
Registered trials
1
Recruiting
2
Unique sponsors
7
Unique IMPs
2
Commercial trials
Drug classes (ATC)
—
ATC code not specified
1
L
Oncology (ATC L)
1
N
Neurology/Psychiatry (ATC N)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Monoclonal antibody (tumor, humanized)
2 substances
IMiD
1 substance
Monoclonal antibody
1 substance
BTK inhibitor
1 substance
Phase II:
1
Phase I/II:
1
Phase II
1 trial-
EndedCelgene Corp. CommercialGOLCADOMIDE
Phase I/II
1 trial-
RecruitingBeOne Medicines AG CommercialBGB-16673; GLOFITAMAB; MOSUNETUZUMAB; N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5- YL)OXY]BENZAMIDE; OBINUTUZUMAB; ZANUBRUTINIB
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Celgene Corp. | Commercial | 1 | Phase II | 0 |
| BeOne Medicines AG | Commercial | 1 | Phase I/II | 1 |
New trials by year
2024
1
2025
1